2018’s Top Biopharma Deal-makers
Even though 2018 did not feature the big influx of biopharma M&A that was expected, there were still encouraging signs that major advancements and breakthroughs in the biotech industry attract buy-outs. Cancer-focused companies and oncology assets again drove volume in alliances and financing transactions.
You may also be interested in...
Merck & Co.’s Keytruda is already elbowing its way into the top ten best-selling drugs. But it, and its expanding cohort of competitors, could be much bigger. Companies and investors are scrambling to identify the technology or technologies that can unlock checkpoint inhibitors’ potential in the 70% or more of tumors where they do not currently work. That activity is reflected across 2018’s licensing deals, M&A and financings.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2020.